Pharmacologically Active Constituents of Chocolate and Their Symptomatic Effects in Patients With Idiopathic Parkinson's Disease (Choc-PD)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02275884 |
Recruitment Status : Unknown
Verified October 2014 by Technische Universität Dresden.
Recruitment status was: Recruiting
First Posted : October 27, 2014
Last Update Posted : October 27, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Parkinson Disease | Dietary Supplement: Dark chocolate (85% cocoa) Dietary Supplement: White chocolate (0% cocoa) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Basic Science |
Official Title: | Evaluation of Plasma Concentrations of Pharmacologically Active Constituents of Chocolate and Their Symptomatic Effects in Patients With Idiopathic Parkinson's Disease |
Study Start Date : | June 2013 |
Estimated Primary Completion Date : | April 2015 |
Estimated Study Completion Date : | June 2015 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Dark chocolate (85% cocoa)
Patients will initially receive 50 grams of dark chocolate (85% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of white chocolate (0% cocoa) b.i.d. for another week.
|
Dietary Supplement: Dark chocolate (85% cocoa) Dietary Supplement: White chocolate (0% cocoa) |
Sham Comparator: White chocolate (0% cocoa)
Patients will initially receive 50 grams of white chocolate (0% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of dark chocolate (85% cocoa) b.i.d. for another week.
|
Dietary Supplement: Dark chocolate (85% cocoa) Dietary Supplement: White chocolate (0% cocoa) |
- Change in plasma concentrations of pharmacologically active constituents of chocolate after one week consumption of dark chocolate in comparison to baseline and to one week consumption of white chocolate [ Time Frame: 7 days ]
- Change in the severity of motor and non-motor symptoms of PD after one week consumption of dark chocolate in comparison to baseline and to one week consumption of white chocolate [ Time Frame: 7 days ]Changes in motor symptoms will be assessed with the UPDRS, changes in non-motor symptoms will be assessed with NMSS and NMSQuest.
- Change in cognitive measures (MoCA, SCOPA-COG) after one week consumption of dark chocolate in comparison to baseline and to one week consumption of white chocolate [ Time Frame: 7 days ]
- Change in depressive symptoms (BDI-II) after one week consumption of dark chocolate in comparison to baseline and to one week consumption of white chocolate [ Time Frame: 7 days ]
- Change in the quality of life (PDQ-39) after one week consumption of dark chocolate in comparison to baseline and to one week consumption of white chocolate [ Time Frame: 7 days ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Female or male individuals aged 40 years and above
- Parkinson's Disease according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria
- Hoehn and Yahr stage I-III
- Minimum score of 16 points in the motor part of the Unified Parkinson Disease Rating Scale (UPDRS part III)
- Stable antiparkinsonian medication for at least 4 weeks prior to study inclusion
- Ability to provide informed consent
Exclusion Criteria:
- Clinical signs for a secondary or atypical Parkinsonian syndrome
- Treatment with any investigational medical product within 30 days prior to study inclusion
- Intake of chocolate or other cocoa-containing products within the last 7 days prior to study inclusion (patients can be re-screened after 7 days of abstinence from chocolate and other cocoa-containing products)
- Known intolerance or allergies against chocolate or other cocoa-containing products
- Diabetes mellitus and/or impaired glucose tolerance in the medical history
- Alcohol or drug abuse in the medical history
- Presence of levodopa-induced motor complications
- Other neurological, psychiatric or miscellaneous conditions that would significantly impair study participation, medical assessments or the consenting process
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02275884
Contact: Matthias Löhle, MD | + 49 351 458 2532 | matthias.loehle@uniklinikum-dresden.de | |
Contact: Alexander Storch, MD | + 49 351 458 2532 | alexander.storch@uniklinikum-dresden.de |
Germany | |
Department of Neurology, Dresden University of Technology | Recruiting |
Dresden, Saxony, Germany, 01307 | |
Contact: Simone Schmidt +49 351 458 2524 ext 2524 simone.schmidt@uniklinikum-dresden.de | |
Principal Investigator: Matthias Löhle, MD | |
Sub-Investigator: Alexander Storch, MD |
Principal Investigator: | Matthias Löhle, MD | Department of Neurology, Dresden University of Technology |
Responsible Party: | Technische Universität Dresden |
ClinicalTrials.gov Identifier: | NCT02275884 |
Other Study ID Numbers: |
EK366112012 |
First Posted: | October 27, 2014 Key Record Dates |
Last Update Posted: | October 27, 2014 |
Last Verified: | October 2014 |
Parkinson Disease Cacao Biogenic amines Xanthines Neurodegenerative Diseases |
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases |